The need for minimization strategies: Current problems of immunosuppression

Transplant International

Volumn 28, Issue 8, 2015, Pages 891-900

  Bamoulid, Jamal ^a   Staeck, Oliver ^a   Halleck, Fabian ^a   Khadzhynov, Dmytri ^a   Brakemeier, Susanne ^a   Dürr, Michael ^a   Budde, Klemens ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

immunosuppressants; kidney transplantation; long term outcomes; minimization; side effects

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; RAPAMYCIN; STEROID; TACROLIMUS;

ACNE; ACUTE GRAFT REJECTION; ASEPTIC NECROSIS; BK VIRUS INFECTION; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; CATARACT; CAUSE OF DEATH; CHRONIC ALLOGRAFT NEPHROPATHY; CONSTIPATION; CUSHING SYNDROME; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG EFFECT; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; EDEMA; EVIDENCE BASED MEDICINE; GINGIVA HYPERTROPHY; GRAFT SURVIVAL; GROWTH RETARDATION; HAIR LOSS; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LOW RISK PATIENT; LYMPHOCELE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; NAUSEA; NEPHRITIS; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK REDUCTION; SKIN ATROPHY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREMOR; VOMITING; WOUND HEALING IMPAIRMENT; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; PROCEDURES; TRANSPLANTATION TOLERANCE; TREATMENT WITHDRAWAL;

DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TRANSPLANTATION TOLERANCE; WITHHOLDING TREATMENT;

EID: 84947033276     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12553     Document Type: Review

References (112)

1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al,. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D,. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
3. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B,. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
4. Weir MR, Mulgaonkar S, Chan L, et al,. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897.
5. Dorje C, Midtvedt K, Holdaas H, et al,. Early versus late acute antibody-mediated rejection in renal transplant recipients. Transplantation 2013; 96: 79.
6. Orandi BJ, Chow EH, Hsu A, et al,. Quantifying renal allograft loss following early antibody-mediated rejection. Am J Transplant 2015; 15: 489.
7. Wiebe C, Gibson IW, Blydt-Hansen TD, et al,. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157.
8. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
9. Ekberg H, Bernasconi C, Tedesco-Silva H, et al,. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876.
10. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
11. Bunnapradist S, Ciechanowski K, West-Thielke P, et al,. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant 2013; 13: 760.
12. Pascual J,. Steroid avoidance or withdrawal in kidney transplantation. Curr Opin Organ Transplant 2011; 16: 600.
13. Grinyo JM, Cruzado JM,. Mycophenolate mofetil and calcineurin-inhibitor reduction: recent progress. Am J Transplant 2009; 9: 2447.
14. Srinivas TR, Meier-Kriesche HU,. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol 2008; 3 (Suppl 2): S101.
15. Chapman JR,. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant 2011; 11: 693.
16. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC,. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810.
17. Almeida CC, Silveira MR, de Araujo VE, et al,. Safety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: a systematic review and meta-analysis. Pharmaceuticals (Basel) 2013; 6: 1170.
18. Silva HT Jr, Yang HC, Abouljoud M, et al,. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595.
19. Ghisdal L, Bouchta NB, Broeders N, et al,. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008; 21: 146.
20. Vincenti F, Friman S, Scheuermann E, et al,. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506.
21. Hirsch HH, Randhawa P,. BK polyomavirus in solid organ transplantation. Am J Transplant 2013; 13 (Suppl. 4): 179.
22. Sawinski D, Goral S,. BK virus infection: an update on diagnosis and treatment. Nephrol Dial Transplant 2015; 30: 209.
23. Bressollette-Bodin C, Coste-Burel M, Hourmant M, Sebille V, Andre-Garnier E, Imbert-Marcille BM,. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. Am J Transplant 2005; 5: 1926.
24. Brennan DC, Agha I, Bohl DL, et al,. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: 582.
25. Wallemacq P, Armstrong VW, Brunet M, et al,. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009; 31: 139.
26. Budde K, Durr M, Liefeldt L, Neumayer HH, Glander P,. Enteric-coated mycophenolate sodium. Expert Opin Drug Saf 2010; 9: 981.
27. Srinivas TR, Kaplan B, Meier-Kriesche HU,. Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 2003; 4: 2325.
28. Maripuri S, Kasiske BL,. The role of mycophenolate mofetil in kidney transplantation revisited. Transplant Rev (Orlando) 2014; 28: 26.
29. Davies NM, Grinyo J, Heading R, Maes B, Meier-Kriesche HU, Oellerich M,. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant 2007; 22: 2440.
30. Cooper M, Salvadori M, Budde K, Oppenheimer F, Sollinger H, Zeier M,. Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. Transplant Rev (Orlando) 2012; 26: 233.
31. Maes B, Hadaya K, de Moor B, et al,. Severe diarrhea in renal transplant patients: results of the DIDACT study. Am J Transplant 2006; 6: 1466.
32. Kotton CN, Kumar D, Caliendo AM, et al,. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333.
33. Halloran PF,. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
34. Bolin P Jr, Shihab FS, Mulloy L, et al,. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results. Transplantation 2008; 86: 88.
35. Frimat L, Cassuto-Viguier E, Charpentier B, et al,. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant 2006; 6: 2725.
36. Murakami N, Riella LV, Funakoshi T,. Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. Am J Transplant 2014; 14: 2317.
37. Kaplan B, Qazi Y, Wellen JR,. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) 2014; 28: 126.
38. Huyghe E, Zairi A, Nohra J, Kamar N, Plante P, Rostaing L,. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int 2007; 20: 305.
39. Braun M, Young J, Reiner CS, et al,. Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial. PLoS One 2012; 7: e45868.
40. Lamb KE, Lodhi S, Meier-Kriesche HU,. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450.
41. Nankivell BJ, Kuypers DR,. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378: 1428.
42. Terasaki PI, Cecka JM,. The center effect: is bigger better? Clin Transpl 1999; 317.
43. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK,. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307.
44. Sarnak MJ, Levey AS, Schoolwerth AC, et al,. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050.
45. Kasiske BL, Maclean JR, Snyder JJ,. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol 2006; 17: 900.
46. Ojo AO,. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82: 603.
47. Cosio FG, Kudva Y, van der Velde M, et al,. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 2415.
48. Courivaud C, Kazory A, Simula-Faivre D, Chalopin JM, Ducloux D,. Metabolic syndrome and atherosclerotic events in renal transplant recipients. Transplantation 2007; 83: 1577.
49. Kasiske BL, Chakkera HA, Roel J,. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735.
50. Halimi JM, Matthias B, Al-Najjar A, et al,. Respective predictive role of urinary albumin excretion and nonalbumin proteinuria on graft loss and death in renal transplant recipients. Am J Transplant 2007; 7: 2775.
51. Abbott KC, Yuan CM, Taylor AJ, Cruess DF, Agodoa LY,. Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14: 2358.
52. Meier-Kriesche HU, Baliga R, Kaplan B,. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291.
53. Fellstrom B, Jardine AG, Soveri I, et al,. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005; 5: 1986.
54. Kaplan B, Meier-Kriesche HU,. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant 2002; 2: 970.
55. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H,. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011; 378: 1419.
56. Liefeldt L, Budde K,. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transpl Int 2010; 23: 1191.
57. Pilmore H, Dent H, Chang S, McDonald SP, Chadban SJ,. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010; 89: 851.
58. Budde K, Matz M, Durr M, Glander P,. Biomarkers of over-immunosuppression. Clin Pharmacol Ther 2011; 90: 316.
59. Fishman JA,. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601.
60. Rama I, Grinyo JM,. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol 2010; 6: 511.
61. Chapman JR, Webster AC, Wong G,. Cancer in the transplant recipient. Cold Spring Harb Perspect Med. 2013; 3: pii: a015677. doi: 10.1101/cshperspect.a015677.
62. Renders L, Heemann U,. Chronic renal allograft damage after transplantation: what are the reasons, what can we do? Curr Opin Organ Transplant 2012; 17: 634.
63. Reinke P, Fietze E, Ode-Hakim S, et al,. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 344: 1737.
64. Muller V, Becker G, Delfs M, Albrecht KH, Philipp T, Heemann U,. Do urinary tract infections trigger chronic kidney transplant rejection in man? J Urol 1998; 159: 1826.
65. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD,. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557.
66. El-Zoghby ZM, Stegall MD, Lager DJ, et al,. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
67. Vlaminck H, Maes B, Evers G, et al,. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant 2004; 4: 1509.
68. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC,. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004; 77: 769.
69. Halloran PF, Chang J, Famulski K, et al,. Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J Am Soc Nephrol 2014; pii: ASN.2014060588. [Epub ahead of print]
70. Lachmann N, Terasaki PI, Schonemann C,. Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up. Clin Transpl 2006: 171.
71. Kim M, Martin ST, Townsend KR, Gabardi S,. Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options. Pharmacotherapy 2014; 34: 733.
72. Ojo AO, Held PJ, Port FK, et al,. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
73. Sharif A, Baboolal K,. Complications associated with new-onset diabetes after kidney transplantation. Nat Rev Nephrol 2012; 8: 34.
74. Pascual J, Royuela A, Galeano C, Crespo M, Zamora J,. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant 2012; 27: 825.
75. Rike AH, Mogilishetty G, Alloway RR, et al,. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin Transplant 2008; 22: 229.
76. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P,. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
77. Haynes R, Harden P, Judge P, et al,. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet 2014; 384: 1684.
78. Hanaway MJ, Woodle ES, Mulgaonkar S, et al,. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909.
79. Cantarovich D, Rostaing L, Kamar N, et al,. Early corticosteroid avoidance in kidney transplant recipients receiving ATG-F induction: 5-year actual results of a prospective and randomized study. Am J Transplant 2014; 14: 2556.
80. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J,. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307.
81. Knight SR, Morris PJ,. Interaction between maintenance steroid dose and the risk/benefit of steroid avoidance and withdrawal regimens following renal transplantation. Transplantation 2011; 92: e63.
82. Knight SR, Morris PJ,. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1.
83. Pascual J, van Hooff JP, Salmela K, Lang P, Rigotti P, Budde K,. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006; 82: 55.
84. Pascual J, Zamora J, Galeano C, Royuela A, Quereda C,. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev. 2009: CD005632.
85. Clayton P, McDonald S, Chadban S,. Steroids and recurrent IgA nephropathy after kidney transplantation. Am J Transplant 2011; 11: 1645.
86. Cohney SJ,. Steroid withdrawal in patients transplanted for IgA nephropathy- A disease-specific consideration? Am J Transplant 2011; 11: 1553.
87. Kamar N, Del Bello A, Belliere J, Rostaing L,. Calcineurin-inhibitor sparing regimens based on mycophenolic acid after transplantation. Transpl Int 2015; doi: 10.1111/tri.12515. [Epub ahead of print]
88. Kamar N, Rostaing L, Cassuto E, et al,. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients. Clin Nephrol 2012; 77: 126.
89. Mathis AS, Egloff G, Ghin HL,. Calcineurin inhibitor sparing strategies in renal transplantation, part one: late sparing strategies. World J Transplant 2014; 4: 57.
90. Roodnat JI, Hilbrands LB, Hene RJ, et al,. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation. Transplantation 2014; 98: 47.
91. Abramowicz D, Del Carmen Rial M, Vitko S, et al,. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234.
92. Suwelack B, Gerhardt U, Hohage H,. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655.
93. Dudley C, Pohanka E, Riad H, et al,. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005; 79: 466.
94. Dieckmann F,. Immunosuppressive minimisation with mTor inhibitors and Belatacept. Transpl Int 2015; in press.
95. Halleck F, Duerr M, Waiser J, et al,. An evaluation of sirolimus in renal transplantation. Expert Opin Drug Metab Toxicol 2012; 8: 1337.
96. Schena FP, Pascoe MD, Alberu J, et al,. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
97. Gatault P, Lebranchu Y,. Conversion to mTOR-inhibitor-based immunosuppression: which patients and when? Transplant Res 2013; 2 (Suppl 1): S3.
98. Budde K, Bunnapradist S, Grinyo JM, et al,. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. Am J Transplant 2014; 14: 2796.
99. Liefeldt L, Brakemeier S, Glander P, et al,. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192.
100. Campistol JM, Albanell J, Arns W, et al,. Use of proliferation signal inhibitors in the management of post-transplant malignancies-clinical guidance. Nephrol Dial Transplant 2007; 22 (Suppl 1): i36.
101. Euvrard S, Morelon E, Rostaing L, et al,. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329.
102. Halleck F, Budde K,. Transplantation: Sirolimus for secondary SCC prevention in renal transplantation. Nat Rev Nephrol 2012; 8: 687.
103. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535.
104. Vanrenterghem Y, Bresnahan B, Campistol J, et al,. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011; 91: 976.
105. Rostaing L, Neumayer HH, Reyes-Acevedo R, et al,. Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes. Clin J Am Soc Nephrol 2011; 6: 2696.
106. Durrbach A, Pestana JM, Pearson T, et al,. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547.
107. Pestana JO, Grinyo JM, Vanrenterghem Y, et al,. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630.
108. Larsen CP, Grinyo J, Medina-Pestana J, et al,. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90: 1528.
109. Rostaing L, Vincenti F, Grinyo J, et al,. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 2013; 13: 2875.
110. Charpentier B, Medina Pestana JO, Del CRM, et al,. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant 2013; 13: 2884.
111. Satyananda V, Shapiro R,. Belatacept in kidney transplantation. Curr Opin Organ Transplant 2014; 19: 573.
112. Grinyo JM, Budde K, Citterio F, Charpentier B,. Belatacept utilization recommendations: an expert position. Expert Opin Drug Saf 2013; 12: 111.